2017
Interleukin-8 in cancer pathogenesis, treatment and follow-up
Alfaro C, Sanmamed MF, Rodríguez-Ruiz ME, Teijeira Á, Oñate C, González Á, Ponz M, Schalper KA, Pérez-Gracia JL, Melero I. Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treatment Reviews 2017, 60: 24-31. PMID: 28866366, DOI: 10.1016/j.ctrv.2017.08.004.Peer-Reviewed Original ResearchConceptsSerum concentrationsInterleukin-8IL-8 serum concentrationsPro-tumoral functionsCancer stem cellsTumor burdenLeukocyte infiltrateCancer immunotherapyIL-8Pharmacodynamic biomarkersTherapeutic combinationsTherapeutic strategiesMyeloid cellsTumor progressionCancer pathogenesisTumor cellsGrowth factorImmunotherapySuch interventionsChemokinesStem cellsCellsInfiltratesCXCR1/2Pathogenesis
2016
Basic Overview of Current Immunotherapy Approaches in Cancer
Velcheti V, Schalper K. Basic Overview of Current Immunotherapy Approaches in Cancer. American Society Of Clinical Oncology Educational Book 2016, 35: 298-308. PMID: 27249709, DOI: 10.1200/edbk_156572.Peer-Reviewed Original ResearchConceptsHost-tumor immune interactionsCurrent immunotherapy approachesPromising new therapeutic strategyRole of immunotherapyImmune checkpoint blockadeHost-tumor interactionsNew therapeutic strategiesCheckpoint blockadeImmunotherapy strategiesImmunotherapy approachesTreatment of cancerCombinatorial immunotherapyImmune interactionsTherapeutic strategiesImmune evasionImmunotherapyCancerMultiple mechanismsMalignancyBlockade
2014
Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights
Velcheti V, Schalper K, Venur V. Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights. Journal Of Receptor Ligand And Channel Research 2014, Volume 8: 1-7. DOI: 10.2147/jrlcr.s39986.Peer-Reviewed Original ResearchPD-1Tumor typesImmune checkpoint inhibitorsDeath-1 (PD-1) pathwayPD-1 ligandsDeath-1/Death 1 ligandDurable antitumor activityImmune checkpoint pathwaysAntigen-presenting cellsPromising anticancer therapeutic strategyPD-L1Immune toleranceInvestigational agentsImmune microenvironmentClinical activityT cellsAnticancer therapeutic strategiesTherapeutic strategiesTherapeutic targetClinical developmentTumor cellsMonoclonal antibodiesAntitumor activityTherapeutic antibodies